Letetresgene autoleucel not checked

GSK

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
2 active
7 in total · 2 in the EU
Targets
 

What this is

How it works
A gene therapy: delivers a gene into the patient's cells so they make a protein they lack.-gene: gene therapy substances WHO name stem
Tested for
Neoplasms
Main trialPhase 2
“This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors.”In the company’s words, NCT03967223 on ClinicalTrials.gov

Other drugs for Neoplasms

All 2440 drugs for Neoplasms

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials7

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 1 Mar 2024 Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors
Phase 2Completed 1 Nov 2021 Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma
Phase 2Completed 12 Oct 2022 Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
Phase 2Completed 1 Mar 2024 Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Phase 1Terminated 13 Jul 2020 Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma
Phase 1Completed 10 Aug 2020 Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase 1Authorised not given Long-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Letetresgene autoleucel

Following is part of Solo: you see every change to Letetresgene autoleucel the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in